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Introduction
I t is stated over and over that epidemiological transition from communicable to non-communicable diseases (NCDs) is an 
evident sign of socioeconomic advancement in developing 
countries.1 However, there is not enough evidences regarding the 
drivers of the transition which are necessary for directing health 
policies and programs at national or sub-national scales.2 The 
Global Burden of Disease (GBD) Studies in 1990, 2000, and 2013 
have revealed that metabolic risk factors are by far the most im-
portant determinants of emerging non-communicable diseases all 
over the world.3–9 
Reliable information on the trends of metabolic risk factors are 
needed for assessing population health status, priority setting, 
and program evaluation.10,11 The trend of metabolic risk factors 
and their attributed burden depicts their pandemic.4,12–16 Based on 
GBD 2010 results, high blood pressure, high total cholesterol, 
high body mass index, and high fasting plasma glucose respec-
tively account for the 53 %, 29 %, 23 %, and 16 % of global 
Disability-Adjusted Life-Year (DALY).4
Developing countries in the Middle East are experiencing a steep 
rise in metabolic risk factors12,13,15,16 leading to situation in which 
this region will observe one of the world’s greatest increases in the 
absolute burden of NCDs and their risk factors in the near future.6
Even though there are trend and point estimations of metabolic 
risk factors for Iranian population8, 15,17–19  there are little informa-
tion about their exposure distribution at sub-national level and no 
information about their trends and their effects on the population 
health.14,15,18
Trend analysis of the metabolic risk factors is a sub-component 
of National and Sub-nation Burden of Diseases, Injuries, and Risk 
Factors from 1990 to 2013 (NASBOD) study in Iran,20 which 
aims to quantify metabolic risk factors exposures and related at-
tributed burdens and their trends and inequalities at national and 
sub-national levels. To the best knowledge of authors of this pa-
per, there are few studies in developed and developing countries 
which provide estimations of trends of the risk factors exposure at 
sub-national (small area estimation) level. 
7KLVSDSHUDLPVWRH[SODLQGH¿QLWLRQVRUJDQL]DWLRQGDWDVRXUF-
es, methods of data gathering or generating, and data on trend 
analysis of the metabolic risk factors in NASBOD study.    
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Methods and Materials
Overview
NASBOD is a multidisciplinary study that was introduced in 
2012 through participation of key stakeholders at national and 
sub-national levels and with the support of Ministry of Health and 
Medical Education of Iran.20 One of the sub groups of NASBOD 
WHDPLVWKHPHWDEROLFULVNIDFWRUVJURXSWKDWKDVEHQH¿WHGIURPOR-
cal and international members and consultants from Tehran Uni-
versity of Medical Sciences, Harvard School of Public Health, 
and Imperial College London.
The team focuses on obesity and overweight, truncal obesity, 
high blood pressure, high blood glucose, hyperlipidemia and 
metabolic syndrome. We chose these risk factors based on the 
magnitude of their exposures, their trends and effect size,14 and 
related data available at national and sub-national levels.17, 18, 21 
We will use mean and standard deviation of metabolic risk factors 
exposure or reported prevalence of high-risk groups for each risk 
factor by sex, age, and year at national and sub-national levels to 
be able to estimate and report the prevalence of metabolic risk 
factors by sex, age, year at national and sub-national form 1990 
to 2013 (Table 1). 
In the next step, using age-standardized prevalence of high-risk 
groups, the socioeconomic or geographical inequalities at nation-
al and sub-national levels will be evaluated. In the last step of 
the study, using directions and magnitudes of risk factors’ effects 
on population health,14 and risk factor exposure distributions, the 
theoretical minimum for each risk factor12,13,15,16 as well as distri-
bution of related DALYs,8,10 and the health effect of each meta-
bolic risk factor will be estimated. For all point estimations the 
VDPSOLQJDQGPRGHOXQFHUWDLQWLHVZLOOEHTXDQWL¿HG,QRUGHUWR
realize the study’s objectives, we have adopted a comprehensive 
strategy for identifying available data sources, quality assess-
ment, data extraction, and analyses. Figure 1 shows an overview 
of the study process.
Data sources
Systematic Literature Review
7KURXJKWKHVFLHQWL¿FSDQHOZHFKRRVH3XE0HG0HGOLQH,Q-
VWLWXWHRI6FLHQWL¿F,QIRUPDWLRQ,6,DQG6&2386DVWKHPDLQ
international electronic data sources. We will search these data 
sources using Mesh terms, Emtree, and related key words to ob-
WDLQWKHPRVWFRPSUHKHQVLYHDQGHI¿FLHQWKLWV
2QWKHRWKHUKDQG,UDQ0HGH[,UDQGRFDQG6FLHQWL¿F,QIRUPD-
tion Database (SID) are chosen from among Iranian databases as 
the comprehensive national electronic data sources covering 89 % 
of Iranian medical and public health journals and with an access 
to gray literature. We will search all databases in order to identify 
population-based studies related to our objectives, published be-
tween 1985 and 2013. We will limit the search terms to adults but 
there is no limitation on language.
Search strategies are presented in appendix A.
In addition to electronic searches, we will consider manual 
searches for reviewing unpublished data sources such as govern-
mental reports, projects’ reports, conferences, and reference lists. 
,QVRPHFDVHVZHZLOOFRQWDFWH[SHUWVLQWKHUHOHYDQW¿HOGVDQG
will ask for more information on their research results.
 
Selection criteria
Our study will include all National, provincial, district and com-
munity based studies from Jan 1985 to Dec 2013, that have re-
ported the mean risk factor exposures in a continuous scale or the 
prevalence / incidence of high risk groups for each risk factors 
in a categorical scale in population level. Our target population 
LVDGXOWV\HDUV7KHVWXGLHVWKDWIRFXVHGRQVSHFLDOSRSX-
lations such as patients, employees, volunteers, immigrants, and 
also hospital-based studies will be excluded. 
Study selection Process
In the study selection process, a reviewer skims the titles. The 
articles that do not look completely remote from our search objec-
tives will be evaluated more in the next level. The abstract review 
phase is designed to identify studies reporting the prevalence, in-
cidence, Mean ± SD and Mean ± SE of metabolic risk factors and 
other related indexes. Abstracts will be excluded if they meet one 
or more exclusion criteria. Then, the articles included based on 
abstract review will undergo independent parallel review to de-
termine if they should be included for data extraction. Disagree-
ments between reviewers regarding article inclusion or exclusion 
will be resolved through consensus adjudication. 
Quality assessment
Quality assessment form has three parts: general information 
about the study, sampling quality, and measurement quality. Each 
study has a unique code and its general information such as the 
name and characteristics of the corresponding author are inserted 
at the top of the form. The sampling quality refers to response 
rate, sample size, and sampling design and the measurement qual-
ity includes type of measurement tools, calibration, and accuracy 
of measurement methods for each risk factor. Accordingly, each 
item obtains a score. For example, table 2  presents the quality 
assessment form of articles related to blood glucose measurement 
and sampling. Based on total score, the quality of article might 
EH UDQNHGDVH[FHOOHQW ±JRRG ±RUSRRU 
The quality score will be calculated for all included papers and its 
¿[HGHIIHFWZLOOFRQWULEXWHWRWKHPRGHO
Data extraction
All included studies will be reviewed and the required informa-
tion will be extracted and inserted in data extraction sheet. As an 
example, the main part of data extraction sheet of blood glucose 
studies is shown in table 3. In brief, the data extraction sheet con-
tains detailed information on mean, standard deviation, standard 
error of mean, and the number of observations for each risk factor 
by age, sex, province/district of the country, year, coverage of the 
study (representativeness), scope of study (rural/urban/both), and 
other related variables such as fasting for fasting plasma glucose.
National Data Sources
National surveys, which are considered as the “secondary data 
sources” in the context of epidemiology and public health, are 
the next important resources of information for this study. One of 
the important surveys is the Non-Communicable Disease Surveil-
lance Survey (NCDSS) following a STEPwise approach based 
on WHO guidelines. The STEP surveys’ data are available for 
6 years until the end of study duration; they are the only com-
plete existing national data sources however they have their own 
shortcomings for instance they have only included consistent and 
XQLTXHGDWD¿OHVDQGWKH\KDYHFOHDQHGDOONLQGRIFRQWDPLQDWHG
data (non-plausible values and outliers).
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Metabolic Risk Factor &ODVVLF'H¿QLWLRQ 3UDFWLFDO'H¿QLWLRQ
High Body Mass Index (BMI)
The body mass index (BMI) is a 
measure for human body shape 
based on an individual’s weight 
and height.
Category
Very severely underweight
Severely underweight
Underweight
Normal (healthy weight)
Overweight
Obese Class I (Moderately obese)
Obese Class II (Severely obese)
Obese Class III (Very severely obese)
BMI range kg/m2
< 15
15.0–16.0
16.0–18.5
18.5–25
25–30
30–35
35–40
!
High Blood Pressure(BP) 
Blood pressure (BP) refers to the 
arterial pressure of the systemic 
circulation.
Category
Hypotension
Desired
Prehypertension
Stage 1 Hypertension
Stage 2 Hypertension
Hypertensive Crisis
systolic, mmHg
< 90
90–119
120–139
140–159
160–179

diastolic, mmHg
< 60
60–79
80–89
90–99
100–109

High Fasting Plasma Glucose 
(FPG)
Blood glucose level is the amount 
of glucose present in the blood.
Category
Normal
Impaired fasting glycaemia
Diabetes mellitus
Fasting glucose 
mg/dl
< 110
110–126
!
Fasting glucose 
mmol/l
< 6.1
6.1–7
!
High Total cholesterol (TC) Total cholesterol is the amount of LDL and HDL in the blood.
Category
Normal blood TC
Borderline blood TC
High blood TC
TC range mg/dl
<200
200–239
!
TC range mmol/l
< 5.2
5.2–6.2
!
Table 1.3UDFWLFDOGH¿QLWLRQRIPHWDEROLFULVNIDFWRUV
Question Response Score
Quality of measurement
Fasting time 
fasting  more than 8= 2
fasting  less than 8 = 0
Method of measurement
Enzyme-based- automated  = 2
Enzyme-based- manual = 1
Chemical –based- manual/not reported=0
Calibration
One center - using one kind of equipments= 2
Multi center -using one kind of equipments= 1
Multi center -using different kinds of equipments/ not reported = 0
Time difference between loading sample and analyzing it
Less than 7 days= 2
More than seven days= 0
Quality of sample
Response rate for taking sample
Over 90% = 6
76-90% = 4
60-75% = 2
Less than 60% / not reported  = 0
Sample size by gender 
over 1000 = 3    
500-1000 = 2
250-500 = 1
Less than 250 = 0
Sampling design
Simple random sampling = +3
2QHVWDJHV\VWHPDWLFFOXVWHUHGRUVWUDWL¿HGVDPSOLQJ 
0XOWLVWDJHFOXVWHUHGVWUDWL¿HG 
TOTAL SCORE 
Table 2. Quality assessment form for blood glucose studies
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ID
Female    
Age_Start
Age_End
Median Age Range
Sample Size
Measure
Blood drawn from 
Vein=1    Capillary=2
Glucose measured in 
Plasma=1  Serum=2    
Whole blood=3
 Measurement method 
lab=1      Portable 
meter=2
Unit
Mean
SD
Lower Level of 95% 
CI
Upper Level of  95% 
CI
SEM
Prevalence of Diabetes 
Mellitus (Percentage)
B
G
-1
00
53
1
19
29
24
13
1
FP
G
1
3
1
m
g/
dl
93
.8
9.
5
_
_
_
0
B
G
-1
00
53
1
30
39
34
.5
24
1
FP
G
1
3
1
m
g/
dl
92
.2
11
.9
_
_
_
1.
4
B
G
-1
00
53
1
40
49
44
.5
34
0
FP
G
1
3
1
m
g/
dl
95
.8
11
.4
_
_
_
8.
3
B
G
-1
00
53
1
50
59
54
.5
27
6
FP
G
1
3
1
m
g/
dl
10
0.
8
13
.7
_
_
_
9.
6
B
G
-1
00
53
1
60
70
65
21
2
FP
G
1
3
1
m
g/
dl
99
.4
13
_
_
_
11
.7
B
G
-1
00
53
0
19
29
24
22
2
FP
G
1
3
1
m
g/
dl
93
.8
13
.6
_
_
_
1.
1
B
G
-1
00
53
0
30
39
34
.5
24
1
FP
G
1
3
1
m
g/
dl
95
.6
12
.3
_
_
_
2.
7
B
G
-1
00
53
0
40
49
44
.5
20
4
FP
G
1
3
1
m
g/
dl
96
.9
12
.9
_
_
_
6.
1
B
G
-1
00
53
0
50
59
54
.5
18
1
FP
G
1
3
1
m
g/
dl
10
3.
1
11
.9
_
_
_
10
.5
B
G
-1
00
53
0
60
70
65
15
2
FP
G
1
3
1
m
g/
dl
10
4.
3
15
.5
_
_
_
12
.5
Ta
bl
e 
3.
 T
he
 m
ai
n 
pa
rt 
of
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at
a 
ex
tra
ct
io
n 
sh
ee
t o
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lo
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tu
di
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Fi
gu
re
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tu
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The second and third national surveys are National Health Sur-
vey (NHS) in 1990 and 2000, and Demographic and Health Sur-
YH\V'+6LQDQGZKLFKPDLQO\FRYHUWKH¿UVWKDOI
of study duration for four distinct years. Nevertheless, one of the 
DHS data sources has not been accessible for the researchers of 
this study so far. We hope that we can attain the consent of its 
trustee before the beginning of analyses phase.
Further Data Sources
In addition to these national data sources and other published 
data, there are other community-based and provincial-based sur-
veys such as Golestan Cohort Study, Tehran Lipid and Glucose 
Study, Isfahan Healthy Heart Program, and Persian Gulf Healthy 
Heart Study as other possible available data. It should be noted 
that sub-national and community studies might systematically dif-
fer from national representative ones because they might be un-
dertaken in low-level or high-level zones and regions for each risk 
factor. They might also have more variation than national studies. 
This kind of variation will be dealt with using models in order to 
include an offset for sub-national and community data which will 
be empirically estimated and will allow weighting all data sources 
in order to give more weight to national data and low weight to 
sub-national and community data.
Dealing with data scarcity
Despite our extensive data searches, many age-sex-province-
years and age-sex-district-years data points are missing, which 
lead to geographical and temporal scarcity of data. Moreover, 
EHFDXVHRIPHDVXUHPHQWGLI¿FXOWLHVDOLWWOHQXPEHURIKHDOWKVXU-
veys has collected data about the measurements of risk factors 
such as serum total cholesterol and fasting blood glucose or they 
KDYHMXVWFROOHFWULVNIDFWRUVGDWDLQDUHDVZLWKVSHFL¿FGLVHDVHV
Some data sources only cover certain age or sex groups, or are 
restricted to either rural or urban populations. The data scarcity 
patterns are vivid for older ages as well. Therefore, we have three 
types of scarcity; geographical, temporal, and old-age scarcity.
We will use a model that will combine information from avail-
able data sources to estimate mean of metabolic risk factors for 
each district × year × age or province × year × age. The model 
“borrows strength” across districts in the same province, across 
provinces in the same sub region, and across sub regions in the 
same regions, also time, age, and covariates to smooth over those 
places in the dataset where information is scarce. More important, 
LWTXDQWL¿HVWKHXQFHUWDLQW\RIWKHUHVXOWLQJHVWLPDWHVZKLFKZLOO
EH UHÀHFWHG LQVOLJKWO\FRQVHUYDWLYHHVWLPDWHVDQGZLGHUXQFHU-
tainty intervals.
It is worth mentioning that we will do all analyses by sex, be-
cause levels of risk factors and trends can differ between men and 
women. 
Statistical methods and analysis plans
It is expected that in contempt of our extensive search and ac-
cess to all national surveys, there will be many provinces without 
data or without provincial representative data for many provinces. 
Moreover, many surveys do not include all age groups, both sex-
es, and/or both rural and urban areas of residency. We developed 
two distinct statistical models including spatio-temporal model 
and multilevel autoregressive model, to estimate mean (whatever 
the measure is) and its uncertainty interval by sex, age, year, and 
SURYLQFH7KHPRGHOVZLOOEH¿OOHGRXWE\GDWDRIVSHFL¿FVH[
age, year, and province and by other sex, ages, years, and prov-
inces. For the provinces, which have become separated from other 
provinces in the desired period of time, the problem of misaligned 
areal units does exist. The problem is going to be addressed in 
both models. We are using two models to make sure that there is 
no model dependency in the results.  
      
Bayesian Multilevel Autoregressive model
Another advanced method to handle previously mentioned 
challenges is Bayesian multilevel autoregressive model.22 In this 
framework, observations are hierarchically nested in districts, 
provinces, sub-regions, regions, and national levels, respectively. 
In this hierarchical model, higher levels borrow information to the 
lower levels and units in each level borrow information to each 
other depending on the degree of data availability. The model con-
siders several different components including linear time trends, 
nonlinear change over time, covariate effects, nonlinearity asso-
ciated with age, heterogeneity of data sources, and age-by-study 
variability. Time-varying district-level or province-level covari-
ates provide the estimates if practical.
Spatio-temporal model
One of the commonly used frameworks to overcome the above-
mentioned issues is Spatio-temporal Bayesian hierarchical mod-
eling with conditional autoregressive (CAR) prior for spatial ran-
dom effects.23 In spatial framework, observations, which are clos-
er in space, are assumed to be more correlated than observations 
farther away. This structure enables model to “borrow informa-
tion” from neighboring areal units to improve estimates for areas 
with missing values and/or with small number of observations. In 
addition, we will employ spatio-temporal misalignment modeling 
to combine incompatible areal units between data sources and/or 
over the years. The model includes covariates effects, non-linear 
age trend, and variations in study quality and source of data.  
In both modeling frameworks, because of general applicability 
and ease of implementation the MCMC methods will be used to 
perform Bayesian inference. All programs will be written in R 
statistical packages (version 3.0.1).
In addition to these challenges, the other problem is about sum-
PDU\VWDWLVWLFV WKDWKDYHEHHQUHSRUWHGZLWKGLIIHUHQWFODVVL¿FD-
tions. Using regression models, we cross walk between continu-
ous and categorical measures of variables of interest.
Ethical considerations
All of the studies that will be included in our review will be cited in 
all reports and all publications of our study. Whenever we need more 
information about a certain study, we will contact the correspond-
ing authors and will obtain the required information via reanalyz-
ing data, which will make the author of that paper our collaborating 
coauthor. It is worth mentioning that our study has been approved 
by the ethical committee of Tehran University of Medical Science.   
Discussion
The current study will have numerous achievements. To put it in 
DQXWVKHOOWKLVVWXG\ZLOOSURGXFHVFLHQWL¿FHYLGHQFHVIRUWKHSUHY-
alence and attributable burden of metabolic risk factors- namely 
systolic blood pressure (SBP), body mass index (BMI), fasting 
plasma glucose (FPG), and total cholesterol (TC) - inequality 
in distribution and burden attributable to these risk factors, their 
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implications for policy making. This study will be conducted at 
sub-national scale so that inequalities between regions will be re-
vealed and health policies and programs can be designed accord-
ingly.24 As mentioned in methodology, several sources of data and 
new quantitative methods will be used for our estimations, so that 
the probable low quality of data will be adjusted. 
The Global Burden of Diseases Study was conducted at regional 
and national levels from 1990 to 2010.4–7,25–31  Consequently, a 
number of studies at national levels were conducted, namely in 
United Kingdom and Australia32,33 and in South Africa and Mex-
ico.34,35 The present study has certain advantages over the afore-
mentioned estimations. First and most importantly, compared with 
previous studies, we have more data points at national and sub-na-
tional levels which make it possible to estimate the prevalence and 
attributable burden of risk factors with higher quality. Second, we 
have built the capacity for research centers and researchers across 
the country to participate in the project, which will provide an op-
portunity to collect high quality data at sub-national scale. 
The national burden of disease study, which was conducted in 
,UDQIRUWKH¿UVWWLPHLQGLGQRWLQFOXGHEXUGHQDWWULEXWDEOH
WRWKHULVNIDFWRUVLQLWVHVWLPDWLRQV7KH¿UVWVWXG\RQEXUGHQDW-
tributable to risk factors was conducted in 2005 and was published 
in 2011; however, the results of this study were regional rather than 
provincial. Moreover, they were cross-sectional.14 Thus, the need 
for reproducing a more comprehensive study after almost a decade 
is evident. Our present study has certain advantages over previ-
ous studies in Iran. Furthermore, in comparison with sub-national 
studies conducted in a number of other countries, our study is su-
perior.33,34 The population-based Non-Communicable Disease Sur-
veillance Survey following a STEPwise approach provides data on 
measured BMI, FPG, SBP, and TC and their trends at national and 
provincial scale.36 Additionally, as mentioned in methods, we have 
access to more comprehensive national studies relative to previous 
burden of disease study in Iran, and thanks to web-based Iranian 
search engines, we have also more access to  a number of commu-
nity-based epidemiological studies at smaller scales are also avail-
able that will be captured by systematic review of published and 
unpublished documents. Based on these data sources, YLD along 
with YLL (and consequently DALYs) can be estimated, which is 
an advantage over other subnational studies that were restricted to 
mortality.32–34 Trends and inequalities can be estimated by prov-
ince, sex, age, and area (rural and urban).     
Our study has certain limitations as well. There is a misalignment 
between the sources of covariates and the source of outcomes of 
interest. The difference in nature of these two sources of data will 
impose evident noise on our estimations. To deal with this prob-
lem, we have developed a number of new statistical models.  
The second limitation affecting our study is scarcity of data on 
FPG and TC since they need blood samples. In the main source 
of the current study, the non-communicable diseases surveillance 
survey, blood samples have been taken just in 2005, 2007, and 
2011, which affects the accuracy of estimates on trends.     
The third limitation threatening our estimations is the fact that 
estimating the joint effect of metabolic risk factors and their joint 
contribution to burden of disease is not possible. In previous stud-
ies, the joint effects have been calculated by assuming that these 
risk factors are independent from each other. The assumption af-
fects the accuracy of estimations. Ultimately, there may be lim-
ited access to the full texts of certain published or unpublished 
epidemiological studies because of unwillingness of authors to 
participate in the study. The problem will partly be dealt with by 
contacting the authors of those studies. 
The knowledge produced on distribution of metabolic risk fac-
tors across the country, regarding the costs of their control, can be 
an invaluable guide for relevant population-based interventions. 
The next step of upcoming plan of Non-Communicable Diseases 
5HVHDUFK&HQWHUZLOO EH HVWLPDWLQJ WKH DOORFDWLYH HI¿FLHQF\ RI
KHDOWKSODQVLQWKH¿HOGRIPHWDEROLFULVNIDFWRUV
The results of the current study can be used for priority setting 
and policy making at both national and sub-national levels. The 
difference in estimated burden between regions has many distinct 
policy implications as both the exposure to the risk factors and 
their attributable burden may be quite different, which requires 
different and relevant health policies and programs at sub-nation-
al level. The inequalities between regions can also be a guide for 
just planning at sub-national level. Finally, the most important 
characteristic of this study is its trend analysis, which can make 
future projections and planning feasible.
This study can provide implications for improving informa-
tion system in our country. By revealing the defects and missing 
points in health information system, the results of the study can 
be used for planning a health infrastructure capable of monitor-
ing exposures to risk factors, their burden, their trend, and conse-
quently can create a platform for planning cost-effective policies 
at sub-national level. The results of the study can be invaluable for 
future research at sub-national and national level, regional, and 
even global level. The knowledge acquired in this study will be 
disseminated at various scales through publications, workshops, 
symposiums, and training courses.
,Q FRQFOXVLRQ WKHSUHVHQW VWXG\ LV WKH¿UVW FRPSUHKHQVLYH V\V-
tematic study on the prevalence, trend, and burden of Metabolic 
Risk Factors (MRFs) for the Iranian population at national and sub-
QDWLRQDO OHYHOV7KH ¿QGLQJV FRXOG SURYLGH SUDFWLFDO LQIRUPDWLRQ
regarding metabolic risk factors and their burden for better health 
policy to reduce the burden of diseases, and to plan cost-effective 
preventive strategies. The results also could be used for future com-
plementary global, regional, national, and sub-national studies. 
Abbreviations
NCDs: Non-communicable diseases; GBD: Global Burden of 
Disease; NASBOD: National and Sub-national Burden of Dis-
ease; MRFs: Metabolic Risk Factors; DALY: Disability-Adjusted 
Life Years; YLL: Years of Life Lost due to premature mortality; 
YLD: Years of Life Lost due to Disability;
Competing Interests
The authors declare that they have no competing interests.
Authors’ Contributions
General designing of the paper was by the NASBOD core team. 
Niloofar Peykari, Sadaf G. Sepanlou, Shirin Djalalinia, Amir 
.DVDHLDQKDGHTXDOFRQWULEXWLRQDVWKH¿UVWDXWKRUV$OOFRDX-
thors had contribution in the general designing of paper, design-
ing of systematic review, primary draft preparation, and revision. 
$OODXWKRUVKDYHJLYHQDSSURYDOWRWKH¿QDOYHUVLRQRIWKHPDQX-
script.
Archives of Iranian Medicine, Volume 17, Number 1, January 201460
1DWLRQDODQGVXEQDWLRQDOEXUGHQRI05)VLQ,UDQ²
Acknowledgments
The study is granted by Ministry of Health and Medical Edu-
cation of Islamic Republic of Iran and Setad-e-EjraieFarmane 
Imam. This article is extracted from Ph.D. students’ thesis. We 
would also like to express thanks to Dr.Masoud Moradi for his 
precise editing of the text and Ms Rosa Haghshenas  for her ef-
forts on managing coordinative and administrative processes. we 
would also like to express thanks to Mr. Ali Rafei for his helpful 
cooperation.
References
1. Tunstall-Pedoe H. Preventing Chronic Diseases. A Vital Investment: 
WHO Global Report. Geneva: World Health Organization, 2005.
2. Chan M. From new estimates to better data. Lancet. 2012; 380(9859): 
2054.
3. Mathers CD, Fat DM, Boerma J. The global burden of disease: 2004 
update: World Health Organization; 2008.
4. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, 
et al. A comparative risk assessment of burden of disease and injury 
attributable to 67 risk factors and risk factor clusters in 21 regions, 
1990–2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet. 2013; 380(9859): 2224 – 2260.
5. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et 
al. GBD 2010: a multi-investigator collaboration for global compara-
tive descriptive epidemiology. Lancet. 2012; 380(9859): 2055 – 2058.
6. Murray CJ, Lopez AD. Alternative projections of mortality and dis-
ability by cause 1990–2020: Global Burden of Disease Study. Lancet. 
1997; 349(9064):1498 – 1504.
7. Murray CJ, Lopez AD. Global mortality, disability, and the contribu-
tion of risk factors: Global Burden of Disease Study. Lancet. 1997; 
349(9063): 1436 – 1442.
8. Alwan A. Global status report on noncommunicable diseases 2010: 
World Health Organization; 2011.
9. Lopez AD. The evolution of the Global Burden of Disease frame-
ZRUNIRUGLVHDVHLQMXU\DQGULVNIDFWRUTXDQWL¿FDWLRQGHYHORSLQJWKH
evidence base for national, regional and global public health action. 
Global Health. 2005; 1(5): 1 – 8.
10. Mathers C, Stevens G, Mascarenhas M. Global health risks: mortal-
ity and burden of disease attributable to selected major risks: World 
Health Organization; 2009.
11. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Se-
lected major risk factors and global and regional burden of disease. 
Lancet. 2002; 360(9343): 1347 – 1360.
12. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan 
MJ, et al. National, regional, and global trends in systolic blood pres-
sure since 1980: systematic analysis of health examination surveys 
and epidemiological studies with 786 country-years and 5· 4 million 
participants. Lancet. 2011; 377(9765): 568 – 577.
13. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et 
al. National, regional, and global trends in fasting plasma glucose and 
diabetes prevalence since 1980: systematic analysis of health examin-
ation surveys and epidemiological studies with 370 country-years and 
2· 7 million participants. Lancet. 2011; 378(9785): 31 – 40.
14. Farzadfar F, Danaei G, Namdaritabar H, Rajaratnam JK, Marcus JR, 
Khosravi A, et al. National and subnational mortality effects of meta-
bolic risk factors and smoking in Iran: a comparative risk assessment. 
Popul Health Metr. 2011; 9(1): 55.
15. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, 
Paciorek CJ, et al. National, regional, and global trends in serum total 
cholesterol since 1980: systematic analysis of health examination sur-
veys and epidemiological studies with 321 country-years and 3· 0 mil-
lion participants. Lancet. 2011; 377(9765): 578 – 586.
16. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek 
CJ, et al. National, regional, and global trends in body-mass index 
since 1980: systematic analysis of health examination surveys and 
epidemiological studies with 960 country-years and 9· 1 million par-
ticipants. Lancet. 2011; 377(9765): 557 – 567.
17. Asgari F, Aghajani H, Haghazali M, Heidarian H. Non-communicable 
diseases risk factors surveillance in Iran. Iran J Public Health. 2009; 
38: 119 – 122.
18. Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghaz-
ali M, Asgari F, et al. Third national Surveillance of Risk Factors of 
Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods 
and results on prevalence of diabetes, hypertension, obesity, central 
obesity, and dyslipidemia. BMC Public Health. 2009; 9(1): 167.
19. Naghavi M, Abolhassani F, Pourmalek F, Lakeh MM, Jafari N, 
Vaseghi S, et al. The burden of disease and injury in Iran 2003. Popul 
Health Metr. 2009; 7(1): 9.
20. Farzadfar F, Delavari A, Malekzadeh R, Mesdaghinia A, Jamshidi 
+56D\\DUL$HWDO1$6%2''HVLJQGH¿QLWLRQVDQGPHW-
rics. Arch Iran Med. 2014; 17(1): 7 – 15.
21. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, 
Alaedini F, et al. Prevalence of Diabetes and Impaired Fasting Glu-
cose in the Adult Population of Iran National Survey of Risk Factors 
for Non-Communicable Diseases of Iran. Diabetes care. 2008; 31(1): 
96 – 98.
22. Kasaeian A, Eshraghian MR, Rahimi Foroushani A, Niakan Kalhori 
SR, Mohammad K, Farzadfar F. Bayesian autoregressive multilevel 
modeling of burden of diseases, injuries and risk factors in Iran 1990 
– 2013. Arch Iran Med. 2014; 17(1): 22 – 27.
23. Parsaeian M, Farzadfar F, Zeraati H, Mahmoudi M,  Rahimighazika-
layeh G, Navidi I, et al. Application of spatio-temporal model to esti-
mate burden of diseases, injuries and risk factors in Iran 1990 – 2013. 
Arch Iran Med. 2014; 17(1): 28 – 33.
24. Di Cesare M, Khang Y-H, Asaria P, Blakely T, Cowan MJ, Farzadfar 
F, et al. Inequalities in non-communicable diseases and effective re-
sponses. Lancet. 2013; 381(9866): 585 – 597.
25. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud 
&HWDO*%'GHVLJQGH¿QLWLRQVDQGPHWULFVLancet. 2012; 
380(9859): 2063 – 2066.
26. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et 
al. Global and regional mortality from 235 causes of death for 20 age 
groups in 1990 and 2010: a systematic analysis for the Global Burden 
of Disease Study 2010. Lancet. 2013; 380(9859): 2095 – 2128.
27. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et 
al. Disability-adjusted life years (DALYs) for 291 diseases and injur-
ies in 21 regions, 1990–2010: a systematic analysis for the Global Bu-
rden of Disease Study 2010. Lancet. 2013; 380(9859): 2197 – 2223.
28. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, 
et al. Common values in assessing health outcomes from disease and 
injury: disability weights measurement study for the Global Burden of 
Disease Study 2010. Lancet. 2013; 380(9859): 2129 – 2143.
29. Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, 
et al. Healthy life expectancy for 187 countries, 1990–2010: a system-
atic analysis for the Global Burden Disease Study 2010. Lancet. 2013; 
380(9859): 2144 – 2162.
30. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et 
al. Years lived with disability (YLDs) for 1160 sequelae of 289 dis-
eases and injuries 1990 – 2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet. 2013; 380(9859): 2163 – 2196.
31. Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, 
/HYLQ5HFWRU$HWDO$JHVSHFL¿FDQGVH[VSHFL¿FPRUWDOLW\LQ
countries, 1970 – 2010: a systematic analysis for the Global Burden of 
Disease Study 2010. Lancet. 2013; 380(9859): 2071 – 2094.
32. Asaria P, Fortunato L, Fecht D, Tzoulaki I, Abellan JJ, Hambly P, et 
al. Trends and inequalities in cardiovascular disease mortality across 
7932 English electoral wards, 1982–2006: Bayesian spatial analysis. 
Int J Epidemiol. 2012; 41(6): 1737 – 1749.
33. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease 
and injury in Australia in the new millennium: measuring health loss 
from diseases, injuries and risk factors. Med J Aust. 2008; 188(1): 36 
– 40.
34. Bradshaw D, Nannan N, Groenewald P, Joubert J, Laubscher R, Ni-
jilana B, et al. Provincial mortality in South Africa, 2000-priority-set-
ting for now and benchmark for the future. S Afr Med J. 2008; 95(7): 
496 – 503.
35. Stevens G, Dias RH, Thomas KJ, Rivera JA, Carvalho N, Barquera S, 
et al. Characterizing the epidemiological transition in Mexico: nation-
al and subnational burden of diseases, injuries, and risk factors. PLoS 
medicine. 2008; 5(6): e125.
36. Bonita R, Magnusson R, Bovet P, Zhao D, Malta DC, Geneau R, et 
al. Country actions to meet UN commitments on non-communicable 
diseases: a stepwise approach. Lancet. 2013. 381(9866): 575 – 584.
Archives of Iranian Medicine, Volume 17, Number 1, January 2014 61
13H\NDUL6*6HSDQORX6K'MDODOLQLDHWDO
High Body Mass Index (BMI)
Search strategy in PubMed/Medline
(“Body Mass Index”[Mesh] OR “Body Mass Index”[All Fields] OR “Overweight”[Mesh]) OR “Overweight”[All Fields] OR “Obesity”[Mesh] OR “Obesity”[All 
Fields] OR “Quetelet* Index”[All Fields] AND (“Iran”[Mesh] OR “iran”[All Fields]) OR Iranian[All Fields] OR I.R.Iran[All Fields] OR “I.R Iran”[All Fields] OR 
(“persia”[MeSH Terms] OR “persia”[All Fields])) AND ((“1985/01/01”[PDAT]: “2013/12/31”[PDAT]) AND “humans”[MeSH Terms])
Search strategy in ISI Web of Science
Time span=1990-2013. Databases=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH.
Topic= (“Body Mass Index” OR “Overweight” OR “Obesity” OR “Quetelet* Index”) AND ( (“Iran” OR Iranian OR I.R.Iran OR “persia”) OR Address= (Iran)) 
Search strategy in Scopus
(TITLE-ABS-KEY (Body Mass Index” OR “Overweight” OR “Obesity” OR “Quetelet* Index”)) AND (TITLE-ABS-KEY (Iran OR Iranian OR I.R.Iran OR Persia) 
25$)),/,UDQ$1'38%<($5!$1'38%<($5
High Blood Pressure (BP)
Search strategy in PubMed/Medline
(“Hypertension”[Mesh] OR (“hypertension”[MeSH Terms] OR “hypertension”[All Fields]) OR (“prehypertension”[MeSH Terms] OR “prehypertension”[All 
Fields]“pre-hypertension”[All Fields] OR “Blood Pressure”[All Fields] OR “systolic pressure”[All Fields] OR “diastolic pressure”[All Fields] OR “pulse pressure”[All 
Fields] OR “hypertensive*”[All Fields]) AND (“Iran”[Mesh] OR “iran”[All Fields]) OR Iranian*”[All Fields] OR I.R.Iran”[All Fields] OR “IR. Iran”[All Fields] OR 
(“persia”[MeSH Terms] OR “persia”[All Fields])) ((“1985/01/01”[PDAT] : “2013/12/31”[PDAT]) AND (“humans”[MeSH Terms]))
Search strategy in ISI Web of Science
Time span=1990-2013. Databases=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH.
Topic= (“Hypertension” OR “prehypertension” OR “Blood Pressure*” OR “pre-hypertension” OR “systolic pressure” OR “diastolic pressure” OR “pulse pressure” 
OR “hypertensive” OR “hypertensives”) AND ( (“Iran” OR Iranian OR I.R.Iran OR “persia”) OR Address= (Iran)) 
Search strategy in Scopus
(TITLE-ABS-KEY (“Hypertension” OR “prehypertension” OR “pre-hypertension” OR “Blood Pressure*” OR “systolic pressure” OR “diastolic pressure” OR “pulse 
SUHVVXUH´25³K\SHUWHQVLYH´25³K\SHUWHQVLYHV´$1'7,7/($%6.(<,UDQ25,UDQLDQ25,5,UDQ253HUVLD25$)),/,UDQ$1'38%<($5!
AND PUBYEAR < 2013
High Fasting Plasma Glucose (FPG)
Search strategy in PubMed/Medline
((“Diabetes Mellitus”[Mesh] OR “Diabetes Mellitus”[All Fields] OR “Hyperglycemia”[Mesh]) OR “Hyperglycemia”[All Fields] OR “Hyperglycemias”[All Fields] 
OR “Glucose Intolerance”[Mesh] OR “Blood Glucose”[Mesh]) AND “Blood Glucose”[All Fields] OR “Blood Sugar”[All Fields] OR “Fasting Plasma Glucose”[All 
Fields] AND (“Iran”[Mesh] OR “iran”[All Fields]) OR Iranian[All Fields] OR I.R.Iran[All Fields] OR “I.R Iran”[All Fields] OR (“persia”[MeSH Terms] OR 
“persia”[All Fields]))  AND ((“1985/01/01”[PDAT] : “2013/12/31”[PDAT]) AND “humans”[MeSH Terms])
Search strategy in ISI Web of Science
Time span=1990-2013. Databases=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH.
Topic= (“Diabetes Mellitus” OR “Hyperglycemia” OR “Hyperglycemias” OR “Glucose Intolerance” OR “Blood Glucose” OR “Blood Sugar” OR “Fasting Plasma 
Glucose” AND ( (“Iran” OR Iranian OR I.R.Iran OR “persia”) OR Address= (Iran)) 
Search strategy in Scopus
(TITLE-ABS-KEY (“Diabetes Mellitus” OR “Hyperglycemia” OR “Hyperglycemias” OR “Glucose Intolerance” OR “Blood Glucose” OR “Blood Sugar” OR 
³)DVWLQJ3ODVPD*OXFRVH´$1'7,7/($%6.(<,UDQ25,UDQLDQ25,5,UDQ253HUVLD25$)),/,UDQ$1'38%<($5!$1'38%<($5
High Total cholesterol (TC)
Search strategy in PubMed/Medline
Hypercholesterolemia”[Mesh] OR (“hypercholesterolaemia”[All Fields] OR “hypercholesterolemia”[MeSH Terms] OR “hypercholesterolemia”[All Fields]) OR 
(“hypercholesterolemia”[MeSH Terms] OR “hypercholesterolemia”[All Fields] OR “hypercholesterolemias”[All Fields]) OR “ blood cholesterol”[All Fields]AND 
(“Iran”[Mesh] OR “iran”[All Fields]) OR Iranian[All Fields] OR I.R.Iran[All Fields] OR “I.R Iran”[All Fields] OR (“persia”[MeSH Terms] OR “persia”[All Fields])) 
AND ((“1985/01/01”[PDAT] : “2013/12/31”[PDAT]) AND “humans”[MeSH Terms])
Search strategy in ISI Web of Science
Time span=1990-2013. Databases=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH.
Topic= (Hypercholesterolemia OR hypercholesterolemias OR “ blood cholesterol”) AND ( (“Iran” OR Iranian OR I.R.Iran OR “persia”) OR Address= (Iran)) 
Search strategy in Scopus
(TITLE-ABS-KEY (“Hypercholesterolemia OR hypercholesterolemias OR “blood cholesterol”)) AND (TITLE-ABS-KEY (Iran OR Iranian OR I.R.Iran OR Persia) 
25$)),/,UDQ$1'38%<($5!$1'38%<($5
Appendix A: Search Strategy of Metabolic Risk Factors
